Market Summary
USD51.06-0.48
Market Closed-0.93%
BSX Alerts
BSX Stock Price
BSX RSI Chart
BSX Valuation
BSX Price/Sales (Trailing)
BSX Profitability
BSX Fundamentals
BSX Revenue
BSX Earnings
Price Action
52 Week Range
34.9854.17
(Low)(High)
Last 7 days
-4.8%
Last 30 days
-0.1%
Last 90 days
8.6%
Trailing 12 Months
27.2%
BSX Financial Health
BSX Investor Care
Peers (Alternatives to Boston Scientific)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 110.8B | 19.0B | -8.78% | 16.43% | 46.98 | 6.01 | 8.73% | 30.37% |
ISRG | 107.5B | 6.4B | 4.05% | 37.44% | 81.96 | 16.72 | 8.89% | -20.19% |
BSX | 74.1B | 13.0B | -0.08% | 27.20% | 106.12 | 5.84 | 7.26% | -32.95% |
BDX | 71.3B | 18.8B | -6.73% | -3.13% | 44.09 | 3.79 | -1.96% | -15.83% |
EW | 49.7B | 5.5B | -6.18% | -16.80% | 33.38 | 9.03 | 2.68% | -3.23% |
| MID-CAP | ||||||||
SWAV | 7.2T | 557.2M | -1.64% | 66.40% | 82.2K | 16.8K | 86.42% | 730.06% |
PEN | 11.7B | 884.6M | 7.85% | 115.97% | 1.8K | 13.2 | 13.08% | 200.12% |
GMED | 5.9B | 1.1B | -8.20% | -19.98% | 34.14 | 5.75 | 11.20% | 53.04% |
IRTC | 3.6B | 430.0M | -11.89% | -12.63% | -34.73 | 8.45 | 26.13% | 15.73% |
TNDM | 1.7B | 794.7M | -29.15% | -60.56% | -8.43 | 2.16 | 7.73% | -3556.34% |
| SMALL-CAP | ||||||||
ATEC | 1.6B | 389.0M | -3.76% | 82.19% | -10.63 | 4.18 | 44.08% | 6.96% |
SILK | 1.2B | 150.7M | -30.80% | 0.49% | -21.65 | 7.87 | 40.31% | 1.80% |
AVNS | 1.1B | 814.3M | -20.14% | -16.22% | 24.47 | 1.34 | 6.96% | 121.89% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
Financials for Boston Scientific
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Revenue | 2.9% | 13,045 | 12,682 | 12,567 | 12,329 | 12,162 |
| Gross Profit | 3.2% | 9,005 | 8,727 | 8,650 | 8,491 | 8,390 |
| Operating Expenses | 2.7% | 7,270 | 7,078 | 7,223 | 7,035 | 7,095 |
| S&GA Expenses | 3.4% | 4,675 | 4,520 | 4,510 | 4,444 | 4,400 |
| EBITDA | 10.3% | 2,747 | 2,490 | 2,739 | 2,544 | - |
| EBITDA Margin | 9.3% | 0.22* | 0.20* | 0.22* | 0.21* | - |
| Earnings Before Taxes | 25.3% | 1,430 | 1,141 | 865 | 1,103 | 907 |
| EBT Margin | 30.7% | 0.09* | 0.07* | 0.09* | 0.07* | - |
| Interest Expenses | -45.5% | 256 | 470 | 493 | 516 | 538 |
| Net Income | 6.9% | 698 | 653 | 884 | 810 | - |
| Net Income Margin | 5.9% | 0.06* | 0.05* | 0.07* | 0.07* | - |
| Free Cahsflow | 69.0% | 938 | 555 | 593 | 928 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Assets | 1.3% | 32,892 | 32,469 | 31,947 | 32,189 | 32,337 |
| Current Assets | -1.0% | 5,704 | 5,760 | 5,144 | 5,083 | 5,065 |
| Cash Equivalents | -17.8% | 763 | 928 | 338 | 276 | 325 |
| Inventory | 9.8% | 2,050 | 1,867 | 1,788 | 1,752 | 1,736 |
| Net PPE | 1.3% | 2,478 | 2,446 | 2,273 | 2,246 | 2,265 |
| Goodwill | 2.7% | 13,269 | 12,920 | 12,852 | 12,883 | 12,949 |
| Current Liabilities | 7.4% | 4,083 | 3,803 | 3,549 | 3,883 | 4,275 |
| Long Term Debt | -4.7% | 8,495 | 8,915 | 8,564 | 8,802 | 9,067 |
| Shareholder's Equity | 3.1% | 18,109 | 17,573 | 17,640 | 17,251 | 16,735 |
| Retained Earnings | 40.0% | -450 | -750 | -876 | -1,050 | -1,296 |
| Additional Paid-In Capital | 0.3% | 20,356 | 20,289 | 20,219 | 20,103 | 20,043 |
| Shares Outstanding | 0.1% | 1,432 | 1,430 | 1,428 | - | - |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Cashflow From Operations | 16.3% | 1,774 | 1,526 | 1,197 | 1,192 | 1,528 |
| Share Based Compensation | 1.4% | 223 | 220 | 214 | 207 | 199 |
| Cashflow From Investing | 54.2% | -921 | -2,011 | -2,289 | -3,271 | -3,242 |
| Cashflow From Financing | -11.5% | -611 | -548 | -557 | -352 | -6.00 |
| Dividend Payments | 0% | 55.00 | 55.00 | 55.00 | 55.00 | 55.00 |
| Buy Backs | - | 0.00 | - | - | - | - |
Risks for BSX
What is the probability of a big loss on BSX?
35.4%
Probability that Boston Scientific stock will be more than 20% underwater in next one year
18.5%
Probability that Boston Scientific stock will be more than 30% underwater in next one year.
16.1%
Probability that Boston Scientific stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does BSX drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Boston Scientific was unfortunately bought at previous high price.
Drawdowns
Returns for BSX
Cumulative Returns on BSX
18.7%
10-Year Cumulative Returns
12.4%
7-Year Cumulative Returns
11.0%
5-Year Cumulative Returns
12.2%
3-Year Cumulative Returns
What are the long-term rolling returns for BSX?
FIve years rolling returns for Boston Scientific.
Annualized Returns
Which funds bought or sold BSX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-05-23 | Toroso Investments, LLC | added | 114 | 3,805,000 | 6,688,000 | 0.11% |
2023-05-23 | Front Row Advisors LLC | unchanged | - | 1,000 | 15,000 | 0.01% |
2023-05-23 | Brookfield Corp /ON/ | reduced | -48.11 | -8,412,860 | 10,754,900 | 0.04% |
2023-05-22 | Raleigh Capital Management Inc. | new | - | 135,281 | 135,281 | 0.07% |
2023-05-22 | Westover Capital Advisors, LLC | reduced | -7.01 | 4,739 | 863,418 | 0.32% |
2023-05-22 | PUTNAM INVESTMENTS LLC | reduced | -1.54 | 338,753 | 10,484,800 | 0.02% |
2023-05-22 | FDx Advisors, Inc. | unchanged | - | - | 415,000 | 0.02% |
2023-05-22 | PUTNAM INVESTMENTS LLC | reduced | -33.83 | -94,343,800 | 237,236,000 | 0.38% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -12.44 | -4,900,380 | 55,631,600 | 0.02% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -0.85 | 32,526,500 | 483,597,000 | 0.16% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
BSX Alerts
Boston Scientific News
Schedule 13G FIlings of Boston Scientific
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | blackrock inc. | 9.6% | 137,802,646 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.29% | 118,773,794 | SC 13G/A | |
| Feb 08, 2023 | massachusetts financial services co /ma/ | 5.8% | 82,467,469 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 4.03% | 57,736,340 | SC 13G/A | |
| Jan 24, 2023 | blackrock inc. | 9.8% | 140,116,265 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 7.83% | 111,621,630 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G | |
| Feb 08, 2022 | blackrock inc. | 9.0% | 127,917,655 | SC 13G/A | |
| Feb 04, 2022 | wellington management group llp | 5.22% | 74,421,509 | SC 13G/A |
BSX Fair Value
Recent SEC filings of Boston Scientific
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| May 25, 2023 | SD | SD | |
| May 23, 2023 | 144 | Notice of Insider Sale Intent | |
| May 17, 2023 | 4 | Insider Trading | |
| May 17, 2023 | 4 | Insider Trading | |
| May 16, 2023 | 144 | Notice of Insider Sale Intent | |
| May 15, 2023 | 144 | Notice of Insider Sale Intent | |
| May 09, 2023 | 8-K | Current Report | |
| May 05, 2023 | 4 | Insider Trading | |
| May 05, 2023 | 4 | Insider Trading | |
| May 05, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for BSX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-05-16 | Fitzgerald Joseph Michael | sold | -3,394,860 | 53.5982 | -63,339 | evp & group pres, cardiology |
2023-05-16 | Fitzgerald Joseph Michael | acquired | 744,527 | 13.08 | 56,921 | evp & group pres, cardiology |
2023-05-15 | Carruthers Wendy | sold | -624,333 | 53.4944 | -11,671 | evp, human resources |
2023-05-15 | Carruthers Wendy | acquired | 94,953 | 14.818 | 6,408 | evp, human resources |
2023-05-04 | Sununu John E | acquired | - | - | 3,946 | - |
2023-05-04 | Zane Ellen M | acquired | - | - | 3,946 | - |
2023-05-04 | Connors Nelda J | acquired | - | - | 3,946 | - |
2023-05-04 | WICHMANN DAVID S | acquired | - | - | 3,946 | - |
2023-05-04 | Dockendorff Charles J | acquired | - | - | 3,946 | - |
2023-05-04 | ROUX DAVID J | acquired | - | - | 3,946 | - |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
BSX Income Statement
2023-03-31Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
|---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
| Net sales | $ 3,389 | $ 3,026 |
| Cost of products sold | 1,040 | 955 |
| Gross profit | 2,349 | 2,071 |
| Operating expenses: | ||
| Selling, general and administrative expenses | 1,215 | 1,060 |
| Research and development expenses | 337 | 319 |
| Royalty expense | 11 | 12 |
| Amortization expense | 203 | 198 |
| Contingent consideration net expense (benefit) | 12 | 12 |
| Restructuring net charges (credits) | 20 | 4 |
| Operating expenses | 1,797 | 1,605 |
| Operating income (loss) | 552 | 466 |
| Other income (expense): | ||
| Interest expense | (65) | (279) |
| Other, net | (43) | (31) |
| Income (loss) before income taxes | 444 | 156 |
| Income tax expense (benefit) | 131 | 45 |
| Net income (loss) | 314 | 110 |
| Preferred stock dividends | (14) | (14) |
| Net income (loss) attributable to noncontrolling interests | 0 | 0 |
| Net income (loss) attributable to Boston Scientific common stockholders | $ 300 | $ 97 |
| Net income (loss) per common share — basic | $ 0.21 | $ 0.07 |
| Net income (loss) per common share — diluted | $ 0.21 | $ 0.07 |
| Weighted-average shares outstanding | ||
| Basic | 1,435.8 | 1,427.8 |
| Diluted | 1,446.0 | 1,438.4 |
BSX Balance Sheet
2023-03-31Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 570 | $ 928 |
| Trade accounts receivable, net | 2,076 | 1,970 |
| Inventories | 2,050 | 1,867 |
| Prepaid income taxes | 296 | 264 |
| Other current assets | 711 | 731 |
| Total current assets | 5,704 | 5,760 |
| Property, plant and equipment, net | 2,478 | 2,446 |
| Goodwill | 13,269 | 12,920 |
| Other intangible assets, net | 6,060 | 5,902 |
| Deferred tax assets | 3,900 | 3,942 |
| Other long-term assets | 1,482 | 1,500 |
| TOTAL ASSETS | 32,892 | 32,469 |
| Current liabilities: | ||
| Current debt obligations | 510 | 20 |
| Accounts payable | 868 | 862 |
| Accrued expenses | 1,918 | 2,160 |
| Other current liabilities | 787 | 761 |
| Total current liabilities | 4,083 | 3,803 |
| Long-term debt | 8,495 | 8,915 |
| Deferred income taxes | 210 | 144 |
| Other long-term liabilities | 1,995 | 2,035 |
| Commitments and contingencies | ||
| Stockholders’ equity | ||
| Preferred stock, $0.01 par value - authorized 50,000,000 shares - issued 10,062,500 shares as of March 31, 2023 and December 31, 2022 | 0 | 0 |
| Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,700,828,873 shares as of March 31, 2023 and 1,696,633,993 shares as of December 31, 2022 | 17 | 17 |
| Treasury stock, at cost - 263,289,848 shares as of March 31, 2023 and December 31, 2022 | (2,251) | (2,251) |
| Additional paid-in capital | 20,356 | 20,289 |
| Accumulated deficit | (450) | (750) |
| Accumulated other comprehensive income (loss), net of tax | 178 | 269 |
| Total stockholders’ equity | 17,850 | 17,573 |
| Noncontrolling interests | 259 | 0 |
| Total equity | 18,109 | 17,573 |
| TOTAL LIABILITIES AND EQUITY | $ 32,892 | $ 32,469 |